203 related articles for article (PubMed ID: 26691888)
1. Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized Trial.
Makimura H; Stanley TL; Suresh C; De Sousa-Coelho AL; Frontera WR; Syu S; Braun LR; Looby SE; Feldpausch MN; Torriani M; Lee H; Patti ME; Grinspoon SK
J Clin Endocrinol Metab; 2016 Mar; 101(3):1123-33. PubMed ID: 26691888
[TBL] [Abstract][Full Text] [Related]
2. Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia.
Hadigan C; Liebau J; Torriani M; Andersen R; Grinspoon S
J Clin Endocrinol Metab; 2006 Nov; 91(11):4438-44. PubMed ID: 16940448
[TBL] [Abstract][Full Text] [Related]
3. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
Santomauro AT; Boden G; Silva ME; Rocha DM; Santos RF; Ursich MJ; Strassmann PG; Wajchenberg BL
Diabetes; 1999 Sep; 48(9):1836-41. PubMed ID: 10480616
[TBL] [Abstract][Full Text] [Related]
4. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
[TBL] [Abstract][Full Text] [Related]
5. Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function.
Halbirk M; Nørrelund H; Møller N; Schmitz O; Gøtzsche L; Nielsen R; Nielsen-Kudsk JE; Nielsen SS; Nielsen TT; Eiskjær H; Bøtker HE; Wiggers H
Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1220-5. PubMed ID: 20709866
[TBL] [Abstract][Full Text] [Related]
6. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
Bajaj M; Suraamornkul S; Romanelli A; Cline GW; Mandarino LJ; Shulman GI; DeFronzo RA
Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
J Clin Endocrinol Metab; 2001 Dec; 86(12):5813-8. PubMed ID: 11739444
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
Eur J Endocrinol; 2003 Dec; 149(6):511-9. PubMed ID: 14640991
[TBL] [Abstract][Full Text] [Related]
9. Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men.
Van Dam PS; Smid HE; de Vries WR; Niesink M; Bolscher E; Waasdorp EJ; Dieguez C; Casanueva FF; Koppeschaar HP
J Clin Endocrinol Metab; 2000 Dec; 85(12):4706-11. PubMed ID: 11134132
[TBL] [Abstract][Full Text] [Related]
10. Lowering plasma free fatty acids with Acipimox mimics the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker diabetic fatty rats.
Blachère JC; Pérusse F; Bukowiecki LJ
Metabolism; 2001 Aug; 50(8):945-51. PubMed ID: 11474483
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
[TBL] [Abstract][Full Text] [Related]
12. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
Bajaj M; Suraamornkul S; Kashyap S; Cusi K; Mandarino L; DeFronzo RA
J Clin Endocrinol Metab; 2004 Sep; 89(9):4649-55. PubMed ID: 15356076
[TBL] [Abstract][Full Text] [Related]
13. Reducing plasma free fatty acids by acipimox improves glucose tolerance in high-fat fed mice.
Ahrén B
Acta Physiol Scand; 2001 Feb; 171(2):161-7. PubMed ID: 11350276
[TBL] [Abstract][Full Text] [Related]
14. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
[TBL] [Abstract][Full Text] [Related]
15. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
Cusi K; Kashyap S; Gastaldelli A; Bajaj M; Cersosimo E
Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1775-81. PubMed ID: 17299078
[TBL] [Abstract][Full Text] [Related]
16. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.
Saloranta C; Groop L; Ekstrand A; Franssila-Kallunki A; Eriksson J; Taskinen MR
Diabet Med; 1993 Dec; 10(10):950-7. PubMed ID: 8306591
[TBL] [Abstract][Full Text] [Related]
17. Effects of GH replacement therapy in adults on serum levels of leptin and ghrelin: the role of lipolysis.
Vestergaard ET; Hansen TK; Nielsen S; Moller N; Christiansen JS; Jorgensen JO
Eur J Endocrinol; 2005 Oct; 153(4):545-9. PubMed ID: 16189176
[TBL] [Abstract][Full Text] [Related]
18. The effect of long-term pharmacological antilipolysis on substrate metabolism in growth hormone (GH)-substituted GH-deficient adults.
Nielsen S; Møller N; Pedersen SB; Christiansen JS; Jørgensen JO
J Clin Endocrinol Metab; 2002 Jul; 87(7):3274-8. PubMed ID: 12107236
[TBL] [Abstract][Full Text] [Related]
19. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects.
Lanzi R; Luzi L; Caumo A; Andreotti AC; Manzoni MF; Malighetti ME; Sereni LP; Pontiroli AE
Metabolism; 1999 Sep; 48(9):1152-6. PubMed ID: 10484056
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of lipolysis stimulates peripheral glucose uptake but has no effect on endogenous glucose production in HIV lipodystrophy.
Lindegaard B; Frøsig C; Petersen AM; Plomgaard P; Ditlevsen S; Mittendorfer B; Van Hall G; Wojtaszewski JF; Pedersen BK
Diabetes; 2007 Aug; 56(8):2070-7. PubMed ID: 17601993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
